-
1دورية أكاديمية
لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل. -
2دورية أكاديمية
لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل. -
3
المؤلفون: Manuela Zanni, Alessandro Massimo Gianni, Massimo Di Nicola, Simona Falorio, Fabio Benedetti, Atto Billio, Cristina Boschini, Andrea Rossi, Valentina Tabanelli, Antonino Mulè, Andrés J.M. Ferreri, Federica Delaini, L. Flenghi, Alessandro Rambaldi, Giorgio La Nasa, Paolo Corradini, Arianna Masciulli, Marco Ladetto, Caterina Patti, Corrado Tarella, Andrea Piccin, Sergio Cortelazzo, Riccardo Bruna, Guido Gini, Claudia Castellino, Francesco Di Raimondo, Anna Maria Barbui, Livio Trentin, Giovanni Negri, Maurizio Frezzato, Stefano Pileri, Marco Chilosi, Giuseppe Gritti, Valerio Zoli
المصدر: Journal of Clinical Oncology. 34:4015-4022
مصطلحات موضوعية: Male, Cancer Research, Lymphoma, medicine.medical_treatment, Gastroenterology, FRONT-LINE THERAPY, Antibodies, Monoclonal, Murine-Derived, 0302 clinical medicine, International Prognostic Index, ACVBP PLUS RITUXIMAB, Prednisone, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, GENE-EXPRESSION, Middle Aged, OPEN-LABEL, Combined Modality Therapy, Diffuse, Treatment Outcome, Oncology, Vincristine, 030220 oncology & carcinogenesis, INTENSIFIED CHEMOTHERAPY, YOUNG-PATIENTS, Female, Rituximab, Lymphoma, Large B-Cell, Diffuse, medicine.drug, Adult, Murine-Derived, medicine.medical_specialty, Adolescent, Aged, Cyclophosphamide, Doxorubicin, Humans, Stem Cell Transplantation, Young Adult, NON-HODGKINS-LYMPHOMA, BONE-MARROW-TRANSPLANTATION, DETUDES DES LYMPHOMES, POOR-PROGNOSIS, Antibodies, 03 medical and health sciences, Internal medicine, Large B-Cell, medicine, Chemotherapy, Intention-to-treat analysis, business.industry, Surgery, Transplantation, business, 030215 immunology
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b4f8d0bb34b3446d2fdefadb74be1e7f
https://doi.org/10.1200/jco.2016.67.2980 -
4
المؤلفون: Pauli Vähämurto, Antti Mäkitie, Marjukka Pollari, Sirpa Leppä, Susanna Mannisto, Marja-Liisa Karjalainen-Lindsberg
المساهمون: HUS Head and Neck Center, Department of Oncology, HUS Comprehensive Cancer Center, ATG - Applied Tumor Genomics, Research Program in Systems Oncology, Research Programs Unit, Korva-, nenä- ja kurkkutautien klinikka, Genome-Scale Biology (GSB) Research Program, Department of Pathology, Helsinki University Hospital Area, Department of Ophthalmology and Otorhinolaryngology
مصطلحات موضوعية: Male, CHOP CHEMOTHERAPY, medicine.medical_treatment, clinical presentation, Kaplan-Meier Estimate, CHOP, Gastroenterology, 0302 clinical medicine, Antineoplastic Combined Chemotherapy Protocols, sinonasal tract, ELDERLY-PATIENTS, education.field_of_study, Hematology, General Medicine, Middle Aged, Prognosis, Immunohistochemistry, 3. Good health, Treatment Outcome, 030220 oncology & carcinogenesis, Disease Progression, YOUNG-PATIENTS, Rituximab, Female, TRIAL, Lymphoma, Large B-Cell, Diffuse, Symptom Assessment, medicine.drug, Adult, medicine.medical_specialty, Vincristine, Cyclophosphamide, Population, Nose Neoplasms, 3122 Cancers, diffuse large B-cell lymphoma, survival, Immunophenotyping, PLUS CYCLOPHOSPHAMIDE, 03 medical and health sciences, Internal medicine, medicine, Humans, NON-HODGKINS-LYMPHOMA, VINCRISTINE, DETUDES DES LYMPHOMES, education, Aged, Neoplasm Staging, Proportional Hazards Models, Chemotherapy, business.industry, medicine.disease, Lymphoma, Doxorubicin, Prednisone, business, Diffuse large B-cell lymphoma, BIOLOGICAL CHARACTERIZATION, Biomarkers, 030215 immunology
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b29734332df955dc0f12485cb7b4488
http://hdl.handle.net/10138/312895 -
5دورية أكاديمية
لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل. -
6دورية أكاديمية
لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل. -
7دورية أكاديمية
لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل. -
8
المصدر: New England Journal of Medicine. 348(24):2396-2406
مصطلحات موضوعية: RISK, 6 CYCLES, 2ND MALIGNANCY, DETUDES-DES-LYMPHOMES, LADULTE H89 TRIAL, ALTERNATING CHEMOTHERAPY, ALKYLATING-AGENTS, COOPERATIVE GROUP, SALVAGE THERAPY, DISEASE
-
9دورية أكاديمية
لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل. -
10
المؤلفون: Aleman, BMP, Raemaekers, JMM, Tirelli, U, Bortolus, R, van't Veer, MB, Lybeert, MLM, Keuning, JJ, Carde, P, Girinsky, T, van der Maazen, RWM, Tomsic, R, Vovk, M, van Hoof, A, Demeestere, G, Lugtenburg, PJ, Schroyens, W, De Boeck, K, Baars, JW, Kluin-Nelemans, JC, Carrie, C, Aoudjhane, M, Bron, D, Eghbali, H, Smit, WGJM, Meerwaldt, JH, Hagenbeek, A, Pinna, A, Henry-Amar, M
المساهمون: Damage and Repair in Cancer Development and Cancer Treatment (DARE), Stem Cell Aging Leukemia and Lymphoma (SALL)
المصدر: New England Journal of Medicine, 348(24), 2396-2406. MASSACHUSETTS MEDICAL SOC
مصطلحات موضوعية: RISK, 6 CYCLES, 2ND MALIGNANCY, DETUDES-DES-LYMPHOMES, LADULTE H89 TRIAL, ALTERNATING CHEMOTHERAPY, ALKYLATING-AGENTS, COOPERATIVE GROUP, SALVAGE THERAPY, DISEASE
